Skip Navigation Links
   
Skip Navigation Links
   

Stage IV / Recurrent Lung Cancer


MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma. EAY131 (NCT02465050)  (MBMC Contact: Missy Kuhn 314-996-5868)  

 First Line 

 

A randomized phase II/III trial of afatinib plus cetuximab versus afatinib alone in treatment-naive patients with advanced, EGFR Mutation positive non-small cell lung cancer  SWOG S1403 (NCT02438722)  (MBMC Contact: Missy Kuhn 314-996-5868)

Maintenance systemic therapy versus consolidative sterotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer: A randomized phases II/III trial  NRG LU002 (NCT03137771) (Cap Region and SE need RT credentialing) (MBMC Contact: Missy Kuhn 314-996-5868)

 

Second Line

 

Call for Sub-Study S1400G consent - A phase II study of Talazoparib (BMN 673) in patients with homologous recombination repair deficiency positive stage IV squamous cell lung cancer

 

Call for Sub-Study S1400-I Consent (no matching biomarker) 

 

 

Randomized Phase III trial of mematine and whole-brain radiotherapy with or without hippocampal avoidance in patients with brain metastases Randomized Phase III trial of mematine and whole-brain radiotherapy with or without hippocampal avoidance in patients with brain metastases  NRG-CC001 (NCT02360215 )  (MBMC Contact:  Diana Christian 314-996-5888)  (Requires radiation oncologist to undergo training and specialized MRIs - approved at MBMC)

Second or Third Line

A phase II trial of trametinib with docetaxel in patients with KRAS mutation positive non-small cell lung cancer (NSCLC) and progressive disease following one or two prior systemic therapies  S1507 (NCT02642042) (MBMC Contact:  Missy Kuhn 314-996-5868) 

 

 

  

 

Lung Cancer Trials in St. Louis, MO
 
 

All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy